Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and Applications

Area of Science:

• Polymer chemistry
• Nanomedicine
• Drug delivery systems

Background:

• Poly(ethylene glycol) (PEG) is a crucial polymer in clinical drug delivery, particularly for anticancer agents.
• PEGylation improves drug properties like solubility, circulation time, and tumor targeting via the EPR effect.
• Numerous PEGylated therapeutics are approved, with extensive clinical data informing future designs.

Purpose of the Study:

• To review synthetic advances in poly(ethylene glycol) (PEG) prodrug conjugation methodologies.
• To discuss FDA-approved PEGylated delivery systems and their clinical applications.
• To highlight PEG-based formulations currently in clinical trials.

Main Methods:

• Review of synthetic strategies for PEG prodrug conjugates.
• Analysis of FDA-approved PEGylated drug delivery systems.
• Compilation of data on PEGylated therapeutics in clinical trials.

Main Results:

• Significant synthetic progress in creating diverse PEG prodrug conjugates.
• Established clinical success and applications of approved PEGylated therapeutics.
• Ongoing development of novel PEGylated formulations for various cancers.

Conclusions:

• Poly(ethylene glycol)ylation remains a cornerstone of advanced drug delivery, especially for oncology.
• Continued innovation in PEG prodrug design promises enhanced therapeutic efficacy and reduced toxicity.
• The clinical translation of PEGylated systems underscores their therapeutic potential.